Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Talks

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Eye (London, England)|January 18, 2023
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|September 19, 2025
Dual site external validation of artificial intelligence-enabled treatment monitoring for neovascular age-related macular degeneration in EnglandHenry David Jeffry Hogg, S James Talks, Justin Engelmann, et al.
Eye (London, England)|December 24, 2024
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohortClare Bailey, Manju Chandran, Richard Gale, et al.
High Altitude Medicine & Biology|March 30, 2022
Baseline Psychological Traits Contribute to Lake Louise Acute Mountain Sickness Score at High AltitudeBenjamin James Talks, Catherine Campbell, Stephanie J Larcombe, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
JAMA Ophthalmology|June 3, 2021
Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular DegenerationMali Okada, Tien Yin Wong, Paul Mitchell, et al.
Journal of Medical Internet Research|January 10, 2023
Stakeholder Perspectives of Clinical Artificial Intelligence Implementation: Systematic Review of Qualitative EvidenceHenry David Jeffry Hogg, Mohaimen Al-Zubaidy, , et al.
Eye (London, England)|February 21, 2025
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Swati Chandak, Sarega Gurudas, Raheeba Mohammed Pakeer, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Retina (Philadelphia, Pa.)|June 16, 2015
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus RecommendationsK Bailey Freund, Jean-François Korobelnik, Robert Devenyi, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Eye (London, England)|January 18, 2023
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|September 19, 2025
Dual site external validation of artificial intelligence-enabled treatment monitoring for neovascular age-related macular degeneration in EnglandHenry David Jeffry Hogg, S James Talks, Justin Engelmann, et al.
Eye (London, England)|December 24, 2024
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohortClare Bailey, Manju Chandran, Richard Gale, et al.
High Altitude Medicine & Biology|March 30, 2022
Baseline Psychological Traits Contribute to Lake Louise Acute Mountain Sickness Score at High AltitudeBenjamin James Talks, Catherine Campbell, Stephanie J Larcombe, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
JAMA Ophthalmology|June 3, 2021
Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular DegenerationMali Okada, Tien Yin Wong, Paul Mitchell, et al.
Journal of Medical Internet Research|January 10, 2023
Stakeholder Perspectives of Clinical Artificial Intelligence Implementation: Systematic Review of Qualitative EvidenceHenry David Jeffry Hogg, Mohaimen Al-Zubaidy, , et al.
Eye (London, England)|February 21, 2025
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Swati Chandak, Sarega Gurudas, Raheeba Mohammed Pakeer, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Retina (Philadelphia, Pa.)|June 16, 2015
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus RecommendationsK Bailey Freund, Jean-François Korobelnik, Robert Devenyi, et al.
Pageof 7